
TVGN Stock Forecast & Price Target
TVGN Analyst Ratings
Bulls say
Tevogen is a promising player in the healthcare industry, with a diversified portfolio of biotechnology, AI, and healthcare services. The company's recent focus on developing biotechnology products and AI-based solutions has put them in a position to potentially generate significant revenue through milestone and royalty payments. With their strong focus on innovation and technology, Tevogen is poised for long-term growth and success in the healthcare market.
Bears say
Tevogen is facing several risks that led to a lowering of the stock's price target and a downgrade from Buy to Hold, including dilution risk and a weaker capital markets position due to the announced 50:1 reverse stock split. Additionally, other risk factors such as Clinical/Regulatory Risk, Partnership and Financial Risk, Commercial Risk, Legal and Intellectual Property Risk, and Market Share Risk could further impact the company's financials. The recent decline in share price may also delay the company's commercialization timeline and create pressure on its capital formation and balance sheet flexibility.
This aggregate rating is based on analysts' research of Semper Paratus Acquisition Corp and is not a guaranteed prediction by Public.com or investment advice.
TVGN Analyst Forecast & Price Prediction
Start investing in TVGN
Order type
Buy in
Order amount
Est. shares
0 shares